Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
RemeGen Co., Ltd. is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of cutting-edge biologic therapies. The firm primarily addresses autoimmune, oncological, and ophthalmic conditions where significant unmet medical needs persist, operating across Mainland China and the United States. Its marketed product lineup includes Telitacicept (RC18), prescribed for systemic lupus erythematosus, an autoimmune condition, and Disitamab Vedotin (RC48), utilized in treating diverse cancer types. Beyond its commercialized offerings, RemeGen boasts a robust pipeline of investigational therapies. Telitacicept (RC18) is in advanced (Phase III) clinical trials for neuromyelitis optica spectrum disorder and rheumatoid arthritis, and in mid-stage (Phase II) trials for IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis. RC28 has successfully completed Phase I studies for ocular conditions like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Furthermore, several candidates are in early-stage (Phase I) development: RC98, a PD-L1 monoclonal antibody, targets solid tumors; RC88 is being evaluated for mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid malignancies; and RC108 is also in trials for diverse solid tumor indications. RemeGen's preclinical pipeline further features compounds like RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198, all designed to address various solid tumors, alongside RC218 and RC228, which are being explored for ophthalmological disorders. Established in 2008, RemeGen maintains its corporate headquarters in Yantai, People's Republic of China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' o